Characteristics of ultrasmall superparamagnetic iron oxides in patients with brain tumors

American Journal of Roentgenology

Volumn 185, Issue 6, 2005, Pages 1477-1486

  Taschner, Christian A ^a   Wetzel, Stephan G ^a   Tolnay, Markus ^a   Froehlich, Johannes ^b   Merlo, Adrian ^a   Radue, Ernst W ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Guerbet AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMINOBENZIDINE; GADOLINIUM; GADOLINIUM PENTETATE; IRON; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; OXIDE;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOCHEMISTRY; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MACROPHAGE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION NECROSIS; SOLID TUMOR; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BRAIN NEOPLASMS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OXIDES;

EID: 33644823404     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.04.1286     Document Type: Article

References (25)

1. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990; 175:489-493
2. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990; 175:494-498
3. Anzai Y, Prince MR. Iron oxide-enhanced MR lymphography: the evaluation of cervical lymph node metastases in head and neck cancer. J Magn Reson Imaging 1997; 7:75-81
4. Bellin MF, Roy C, Kinkel K, et al. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles-initial clinical experience. Radiology 1998; 207:799-808
5. Mack MG, Balzer JO, Straub R, Eichler K, Vogl TJ. Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. Radiology 2002; 222:239-244
6. Anzai Y, Prince MR, Chenevert TL, et al. MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent. J Magn Reson Imaging 1997; 7:209-214
7. Loubeyre P, Zhao S, Canet E, Abidi H, Benderbous S, Revel D. Ultrasmall superparamagnetic iron oxide particles (AMI 227) as a blood pool contrast agent for MR angiography: experimental study in rabbits. J Magn Reson Imaging 1997; 7:958-962
8. Hoffmann U, Loewe C, Bernhard C, et al. MRA of the lower extremities in patients with pulmonary embolism using a blood pool contrast agent: initial experience. J Magn Reson Imaging 2002; 15:429-437
9. Ahlstrom KH, Johansson LO, Rodenburg JB, Ragnarsson AS, Akeson P, Borseth A. Pulmonary MR angiography with ultrasmall superparamagnetic iron oxide particles as a blood pool agent and a navigator echo for respiratory gating: pilot study. Radiology 1999; 211:865-869
10. Enochs WS, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imaging 1999; 9:228-232
11. Varallyay P, Nesbit G, Muldoon LL, et al. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. AJNR 2002; 23:510-519
12. Weissleder R, Cheng HC, Bogdanova A, Bogdanov A Jr. Magnetically labeled cells can be detected by MR imaging. J Magn Reson Imaging 1997; 7:258-263
13. Zimmer C, Weissleder R, Poss K, Bogdanova A, Wright SC Jr, Enochs WS. MR imaging of phagocytosis in experimental gliomas. Radiology 1995; 197:533-538
14. Zimmer C, Wright SC Jr, Engelhardt RT, et al. Tumor cell endocytosis imaging facilitates delineation of the glioma-brain interface. Exp Neurol 1997; 143:61-69
15. Dousset V, Ballarino L, Delalande C, et al. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis. AJNR 1999; 20:223-227
16. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003; 63:122-125
17. Tropres I, Grimault S, Vaeth A, et al. Vessel size imaging. Magn Reson Med 2001; 45:397-408
18. Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 1998; 40:793-799
19. 90Y-labeled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging 2002; 29:486-493
20. Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002; 224:797-803
21. Kleihues P, Cavenee W. Pathology and genetics of tumours of the nervous system. Lyon, MD: IARC Press, 2000
22. Michel SC, Keller TM, Frohlich JM, et al. Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology 2002; 225:527-536
23. Le Due G, Peoc'h M, Remy C, et al. Use of T(2)-weighted susceptibility contrast MRI for mapping the blood volume in the glioma-bearing rat brain. Magn Reson Med 1999; 42:754-761
24. Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995; 34:555-566
25. Cha S, Knopp EA, Johnson G, Wetzel SG, Litt AW, Zagzag D. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002; 223:11-29